2012-09-26 15:10:50 -
Avastin fails to top any individual market in 2011
The high level of commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. Treatment of cancer has shifted toward a more focused attack on the disease with targeted therapies. However, austerity packages imposed could see slower commercial growth and larger generic erosion of key brands.
Scope
* Analysis of the top 20 oncology therapy brands in the seven major markets
* In depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major markets
* Sales forecasts for the top 20 cancer therapy brands from 2011 to 2021
* Brand dynamics and assessment of the top 5 cancer brands in the seven major
markets
Full Report Details at
-
www.fastmr.com/prod/464845_market_and_product_forecasts_top_20_o ..
Highlights
The total sales of the top 20 cancer therapy brands in the seven major markets was $37.2bn in 2011, with targeted therapies representing 74% of those sales. However, the oncology market is fragmenting as developers focus on niche subsets of patients with specific genetic mutations, making it harder for drugs to reach blockbuster status.
Targeted therapies dominated the market, and will increase their share of the top 20 as patent expiries continue to impact sales of other drug classes. Generic erosion of multiple key brands in the cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales from 17% in 2011 to 10% in 2021.
Avastin did not achieve the top position in any of the individual markets, the US, Japan, or 5EU, due to a combination of US indication removal, cost-conservative EU markets, strong antihormonal sales in Japan, and tough Swiss Franc exchange rates.
Reasons to Get this Report
* Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2011 and 2021.
* Acquire an account of top-selling cancer brand dynamics and the events that drive and limit their market growth.
* The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top 20 forecasts for the US, Japan and 5EU.
Partial Table of Contents:
OVERVIEW
* Catalyst
* Summary
EXECUTIVE SUMMARY
* Strategic scoping and focus
* Datamonitor key findings
* Related reports
MARKET DEFINITION
* Market definition for cancer therapies
* Antihormonal therapies by ATC class
* Cytotoxic therapies by ATC class
* Targeted therapies by ATC class
* Forecast methodology and assumptions
* Methodology flow
* Patent expiries
* Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
* Cancer therapy brands included in this report
* Seven major markets top 20 oncology therapy brands
* Targeted therapies will continue to control the seven major markets top 20
* US top 20 oncology therapy brands
* Cytotoxic brands lose out following patent expiries as targeted therapies fragment the market
* Japan top 20 oncology therapy brands
* Patent expiries are likely to become more significant over the forecast period
* Five major EU markets top 20 oncology therapy brands
* Economic constraints limit sales growth of targeted therapies
PRODUCT FORECASTS
* Brand dynamics
* Avastin maintains overall leading position despite not topping any of the markets in 2011
* Avastin (bevacizumab; Roche/Chugai)
* Forecast assumptions
* Avastin forecast 2011-21
* Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
* Forecast assumptions
* Rituxan forecast 2011-21
* Herceptin (trastuzumab; Roche/Chugai)
* Forecast assumptions
* Herceptin forecast 2011-21
* Gleevec (imatinib; Novartis)
* Forecast assumptions
* Gleevec forecast 2011-21
* Revlimid (lenalidomide; Celgene)
* Forecast assumptions
* Revlimid forecast 2011-21
* Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
* Forecast assumptions
* Erbitux forecast 2011-21
* Lupron (leuprolide; Takeda/Abbott)
* Forecast assumptions
* Lupron forecast 2011-21
BIBLIOGRAPHY
* Journal papers
* Websites
* Datamonitor reports
APPENDIX
* Forecast methodology
* Volume and value forecast methodology
* Price assumptions
TABLES
* Table: Definition of the cancer market, 2012
* Table: Patent expiry dates for antihormonal therapies in the top 20, 2011-21
* Table: Patent expiry dates for cytotoxic therapies in the top 20, 2011-21
* Table: Patent expiry dates for targeted therapies in the top 20, 2011-21
* Table: Drugs included in the top 20 cancer therapy brands, 2011-21
* Table: Sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011
* Table: Forecast sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011-21
* Table: Sales of the top 20 cancer therapy brands in the US, 2011
* Table: Forecast sales of the top 20 cancer therapy brands in the US ($m), 2011-21
* Table: Sales of the top 20 cancer therapy brands in Japan, 2011
* Table: Forecast sales of the top 20 cancer therapy brands in Japan ($m), 2011-21
*
Full Table of Contents is available at:
--
www.fastmr.com/catalog/product.aspx?productid=464845&dt=t
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at
www.fastmr.com/catalog/publishers.aspx?pubid=1002
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
